3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
3
Urinary Bladder Neoplasms
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
1
Carcinoma, Transitional Cell
1
Breast Cancer Metastatic
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
26
Nivolumab
18
enfortumab vedotin
7
avelumab
6
atezolizumab
6
Ipilimumab
6
Magnetic Resonance Spectroscopy
5
fludarabine
4
cabozantinib
4
Gemcitabine
4
Cyclophosphamide
4
Carboplatin
4
Specimen Handling
3
Interleukin-2
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
aldesleukin
2
Platinum
2
Pemetrexed
2
Paclitaxel
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Disulfides
2
Cisplatin
2
Albumin-Bound Paclitaxel
2
vinflunine
1
veliparib
1
valrubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Transitional Cell
×
Rogaratinib
×
Clear all
NCT03473756
2025-04-09
FORT-2
Bayer
Phase 1
Completed
37 enrolled
15 charts